Hikal Limited (HIKAL) Q2 FY27 Financial Results: Revenue ₹403 Cr(2 announcements)

Hikal Limited reported consolidated revenue of ₹403 crores for Q1 FY27, up 6.2% YoY, with EBITDA margin expanding 260 bps to 9.2%. Pharmaceutical revenue grew 15.2% YoY to [amount context mismatch] crores, driven by oncology and CNS APIs, while crop protection saw volume growth offset by input cost pressures. The company achieved EcoVadis Gold rating and commissioned a new cGMP pilot plant in Pune. Forward-looking statements highlight confidence in stepwise recovery through FY27, supported by CDMO pipeline expansion and regulatory progress.

Hikal Limited reported consolidated revenue of ₹403 crores for Q1 FY27, up 6.2% YoY, with EBITDA at ₹37 crores reflecting a 47.4% YoY increase and margin expansion to 9.2%. The Pharmaceutical segment grew 15.2% YoY to [amount context mismatch] crores, driven by higher CDMO and regulated market demand, while Crop Protection revenue reached ₹170 crores amid margin pressure from input cost inflation. The company received EcoVadis Gold recognition and highlighted progress on its remediation plan with the US FDA, alongside investments in CDMO capabilities and sustainability initiatives. Forward-looking statements indicate confidence in sequential revenue and profitability recovery during FY27, supported by improved demand visibility and expanded CDMO opportunities.